A Non-inferiority Open-labelled Crossover Randomized Controlled Trial, of Two Arms, to Investigate the Adhesiveness and Safety of Rotigexole 8 mg/24 Hours Transdermal Patch, Manufactured by Eva Pharma, Egypt, Compared to the Innovator Product, Neupro 8 mg/ 24 Hours Transdermal Patch, Manufactured by UCB Pharma S.A., Belgium, After 24 Hours of Application
Latest Information Update: 19 Jun 2025
At a glance
- Drugs Rotigexole (Primary) ; Rotigotine (Primary)
- Indications Parkinson's disease
- Focus Pharmacokinetics
- Acronyms START
- Sponsors Eva Pharma
Most Recent Events
- 19 Jun 2025 New trial record